The proto-oncogene expression varies over the course of chronic myeloid leukemia

References

• Kantarjian HM, Keating MJ, Talpaz M et al. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med 1987; 83: 445–454.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia. A concise update. Blood 1993; 82: 691–703.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Dixon D, Keating MJ et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1998; 61: 1441–1446.
   Web of Science ®Google Scholar
• Broudy VC. Stem cell factor and hematopoiesis. Blood 1997; 90: 1345–1364.
   PubMed Web of Science ®Google Scholar
• Moore J, Boswell S, Hoffman R et al. Mutant H-Ras over-expression inhibits a random apoptotic nuclease in myeloid leukemia cells. Leuk Res 1993; 17: 703–709.
   PubMed Web of Science ®Google Scholar
• Moore S, Haylock D, Leuesque JP et al. Stem cell factor as a singleagent induces selective proliferation of the Philadelphia chromo-some positive fraction of chronic myeloid leukemia CD34 + cells. Blood 1998; 92: 2461–2470.
   PubMed Web of Science ®Google Scholar
• Moore S, McDiarmid LA and Hughes TP. Stem cell factor and chronic myeloid leukemia CD34+ cells. Leuk Lymphoma 2000; 38: 211–220.
   PubMed Web of Science ®Google Scholar
• Muroi K, Nakamura M, Amemiya Y et al. Expression of c-kit receptor (CD117) and CD34 in leukemic cells. Leuk Lymphoma 1995; 16: 297–305.
   PubMed Web of Science ®Google Scholar
• Hallek M, Herbst R, Danhauser-Riedl S et al. Interaction of thereceptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells. Br J Haematol 1996; 94: 5–16.
   PubMed Web of Science ®Google Scholar
• Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. New Engl J Med 2003; 349: 1451–1464.
   PubMed Web of Science ®Google Scholar
• Deininger MWN, Druker BJ. Specific targeted therapy of chronicmyelogenous leukemia with imatinib. Pharmacol Rev 2003; 55: 401–423.
   PubMed Web of Science ®Google Scholar
• Etten RAY. Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk Res 2004; 2851: S21–S28.
   Google Scholar
• Ceballos E, Delgado MD, Gutierrez Petal. C-myc antagonizes the effect of p53 on apoptosis and p21 WAF1 transformation in K562 leukemic cells. Oncogene 2000; 19: 2194–2204.
   PubMed Web of Science ®Google Scholar
• Shet AS, Jahagirdar BN, Verfaillie CM. Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia 2002; 16: 1402–1411.
   PubMed Web of Science ®Google Scholar
• Beck Z, Kiss A, Toth FD et al. Alterations of p53 and RB genes and the evolution of the accelerated phase of chronic myeloid leukemia. Leuk Lymphoma 2000; 38: 587–597.
   PubMed Web of Science ®Google Scholar
• Sakamuro D, Evinev V, Elliott KJ et al. C-myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms. Oncogene 1995; 11: 2411.
   PubMedGoogle Scholar
• Wang J, Chenivesse X, Henglein B, Brechot C. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature 1990; 343: 555–557.
   PubMed Web of Science ®Google Scholar
• Kramer A, Hochhaus A, Saussehe A; et al. Cyclin Al is predominantly expressed in hematological malignacies with mye-loid differentiation. Leukemia 1998; 12: 893–898.
   PubMed Web of Science ®Google Scholar
• Muller C, Yang R, Beck-von-Pelloz L, Koeffler HP. Cell cycle regulated transcription of the promoter in the human cyclin Al gene. Blood 1997; 90(Suppl 1): 315a.
   Google Scholar
• Reuter CWR, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematological malignancies? Blood 2000; 96: 1655–1669.
   PubMed Web of Science ®Google Scholar
• Morgan MA, Dolp O, Reuter CWM. Cell-cycle-dependent activation of mitogen-activated protein kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of Ras signaling. Blood 2001; 97: 1823–1834.
   PubMed Web of Science ®Google Scholar
• Fernandes RS, Gorman AM, McGahon A et al. The repression of apoptosis by activated abl oncogenes in chronic myelogenous leukemia. Leukemia 1996; 10(Suppl. 2): 17–21.
   Google Scholar
• Kelman Z, Prokocimer M, Peller S et al. Rearrangement in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia. Blood 1989; 74: 2318–2324.
   PubMed Web of Science ®Google Scholar
• Cosman J, Schlegel R. P53 in the diagnosis of human neoplasis. J Nat Cane Inst 1991; 83: 980–981.
   PubMed Web of Science ®Google Scholar
• Soussi T, Legros Y, Lubin R et al. Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 1994; 57: 1–9.
   PubMed Web of Science ®Google Scholar
• Fenaux P. The clinical significance of mutations of the p53 tumor suppressor gene in hematological malignancies. Br J Haematol 1997; 98: 502–511.
   PubMed Web of Science ®Google Scholar
• Ahuja H, Bar-Eli M, Advani SH et al. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci USA 1989; 86: 6783–6787.
   PubMed Web of Science ®Google Scholar
• Nigro JM, Baker Si, Preisinger AC et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342: 705–708.
   PubMed Web of Science ®Google Scholar
• Brusa G, Benvenuti M, Mazzacurati L et al. P53 loss of function enhances genomic instability and accelerated clonal evolution of murine myeloid progenitors expressing the p210BCR-ABL tyrosine kinase. Haematologica 2003; 88: 622–630.
   PubMed Web of Science ®Google Scholar
• Iscobe M, Emanuel BS, Givol D et al. Localization of gene for human p53 tumor antigen to band 17p13. Nature 1986; 320: 84–85.
   PubMed Web of Science ®Google Scholar
• Nakai H, Misawa S. Chromosome 17 abnormalities and inactiva-tion of the p53 gene in chronic myeloid leukemia and their prognostic significance. Leuk Lymphoma 1995; 19: 213–221.
   PubMed Web of Science ®Google Scholar
• Guinn BA, Mills KI. P53 mutations, methylation and genomic instability in the progression of chronic myeloid leukemia. Leuk Lymphoma 1997; 26: 211–226.
   PubMed Web of Science ®Google Scholar
• Matioli GT. On a mechanism for isochromosome 17q in a subset of Ph+ chronic myeloid leukemia patients. Med Hypotheses 1998; 50: 375–383.
   PubMed Web of Science ®Google Scholar
• Blandino G, Scardigli R, Rizzano MG et al. Wild-type p53 modulates apoptosis of normal IL-3 deprived, hematopoietic cells. Oncogene 1995; 10: 731–737.
   PubMed Web of Science ®Google Scholar
• Stuppia L, Calabrese G, Peila R et al. P53 loss and point mutations are associated with suppression of apoptosis and progression of CML into myeloid blastic crisis. Cancer Genet Cytogenet 1997; 98: 28–35.
   PubMed Web of Science ®Google Scholar
• Klobusicka M, Kusenda J, Babusikova O. Expression of p53 and bc1-2 proteins in acute leukemias: an immunocytochemical study. Neoplasma 2001; 48: 489–495.
   PubMed Web of Science ®Google Scholar
• Legros L, Bourcier C, Jacquel A et al. Imatinib mesylate (STI571) decrease the vascular endothelial growth factor plasma concentra-tion in patients with chronic myeloid leukemia. Blood 2004; 104(2): 495–501.
   PubMed Web of Science ®Google Scholar
• Aguayo A, Estey E, Kantarjian H et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999; 94: 3713–3721.
   Web of Science ®Google Scholar
• Aguayo A, Kantarjian H, Manshouki T et al. Angiogenesis in acute chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240–2245.
   PubMed Web of Science ®Google Scholar
• Di Raimondo F, Palumbo GA, Molica S et al. Angiogenesis in chronic myeloproliferative disease. Acta Haematol 2001; 106: 177–183.
   PubMed Web of Science ®Google Scholar
• Ratajczak MZ, Ratajczak J, Machalinski B et al. Role of vascular endothelial growth factor (VEGF) and placenta-derived growth factor (PIGF) in regulating human haemopoietic cell growth. Br J Haematol 1998; 103: 969–979.
   PubMed Web of Science ®Google Scholar
• Canellos G. Diagnosis and treatment of chronic granulocytic leukemia. In: Wiernik PH, Canellos GP, Kyle RA et al. (eds.). Neoplastic Diseases of the Blood. New York: Churchill Livingstone, 1991; 61–76.
   Google Scholar
• Cervantes F, Lopez-Gruillermo A, Bosch F et al. An assessment of the clinico-hematological criteria for the accelerated phase of chronic myeloid leukemia. Eur J Hematol 1996; 57: 286–291.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Hernandez-Boluda JC, Ferrer A et al. The changing profile of Ph-positive chronic myeloid leukemia at presentation: possible impact of erlier diagnosis on survival. Haematologica 1999; 84: 324–327.
   PubMed Web of Science ®Google Scholar
• Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell 1992; 70: 901–910.
   PubMed Web of Science ®Google Scholar
• Paterlini P, Suberville AM, Zindy F et al. Cyclin Al expression in human hematological malignacies: a new marker of cell prolifera-tion. Cancer Res 1993; 53: 235–238.
   PubMed Web of Science ®Google Scholar
• Binet JL, Mentz F and Marle-Beral H. Apoptosis in blood dosease review-new data. Hematol Cell Ther 1996; 38: 253–264.
   PubMedGoogle Scholar
• Wickramasinghe RG, Hoffbrand AV. The molecular basis of leukemia and lymphoma. In: Hoffbrand AV, Lewis SM, Tuddenham EGD (eds.). Postgraduate Haematology, 4th ed. Oxford: Butterworth Heinemann 1999; 354-372.
   Google Scholar
• Vertovsek S, Kantarjian H, Manshouri T et al. Prognostic significance of cellular vascular endothelial growth factor expres-sion in chronic phase chronic myeloid leukemia. Blood 2002; 99: 2265–2267.
   PubMed Web of Science ®Google Scholar
• Sokal JE, Cox EB, Baccarini M et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984; 63: 789–799.
   PubMed Web of Science ®Google Scholar
• Hasford J, Pfirmann M, Hehlmann R et al. A new prognostic score for survival of patients with chronic myelogenous leukemia treated with interferon alfa. Writing Committe for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850–858.
   PubMed Web of Science ®Google Scholar